TAK-456 | 181869-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: TAK-456
• 英文别名: 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone；1-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-3-[4-(tetrazol-1-yl)phenyl]imidazolidin-2-one
• CAS: 181869-54-5
• 化学式: C₂₂H₂₁F₂N₉O₂
• 分子量: 481.465
• InChiKey: JTNIHNJCRCYZSU-IVZQSRNASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  溴甲基乙酸酯 、 TAK-456 在 silica gel 、 正己烷 、 乙醇 、 4-acetoxymethyl-1-[(2R,3R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-tetrazol-1-yl)phenyl]-1-imidazolidinyl]butyl]-1H-1,2,4-triazolium bromide 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以to give 4-acetoxymethyl-1-[(2R,3R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-tetrazol-1-yl)phenyl]-1-imidazolidinyl]butyl]-1H-1,2,4-triazolium bromide (Compound 11, 0.39 g) as colorless crystals的产率得到4-acetoxymethyl-1-[(2R,3R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-tetrazol-1-yl)phenyl]-1-imidazolidinyl]butyl]-1H-1,2,4-triazolium bromide
  参考文献：
  名称：

  Azole compounds, their production and their use

  摘要：

  一种四元氮含量的咪唑-1-基或1,2,4-三唑-1-基化合物，其中构成唑环的氮原子之一被季铵化基取代，该取代基能够在体内被消除并转化为抗真菌唑类化合物。该化合物在水中的溶解度提高，可优选用于注射，具有改善的内部吸收性能，可望对疾病的治疗或预防产生良好效果。

  公开号：

  US06407129B1
• 作为产物：
  描述：

  1-(2-chloroethyl)-1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazoyl)phenyl]urea 在 三乙胺 作用下， 以 N,N-二甲基乙酰胺 、 乙酸乙酯 为溶剂， 反应 3.0h， 以71%的产率得到TAK-456
  参考文献：
  名称：

  光学活性抗真菌唑类。十一。1的替代合成路线。

  摘要：

  光学活性抗真菌三唑1-[（（1R，2R）-2-（2,4-二氟苯基）-2-羟基-1-甲基-3-（1H-1,2,4-三唑）的合成新路线-1-基）丙基] -3- [4-（1H-1-四唑基）苯基] -2-咪唑啉酮（1b）和3-14-（1H-1,2,3-三唑-1-基）建立了具有咪唑烷核的苯基] -2-咪唑啉酮类似物（1a）。关键的合成中间体（2R，3R）-3-（2,2-二乙氧基乙基）氨基-2-（2,4-二氟苯基）-1-（1H1,2,4-三唑-1-基）-2-丁醇（8）和（2R，3R）-2-（2,4-二氟苯基）-3-（2-h羟乙基）氨基-1-（1H-1,2,4-三唑-1-基）-2通过环氧乙烷（2）与相应的2-取代的乙胺的开环反应制备-丁醇（14）。缩醛（8）与氨基甲酸酯（10a，缩合）转化为咪唑烷酮（1a，b），b），然后用盐酸处理，然后进行催化氢化。或者，通过两个反应步骤由羟乙基氨基中间体（14）制备

  DOI：

  10.1248/cpb.48.1947

文献信息

• Optically Active Antifungal Azoles. XII. Synthesis and Antifungal Activity of the Water-Soluble Prodrugs of 1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone.
  作者：Takashi ICHIKAWA、Tomoyuki KITAZAKI、Yoshihiro MATSUSHITA、Masami YAMADA、Ryogo HAYASHI、Masashi YAMAGUCHI、Yutaka KIYOTA、Kenji OKONOGI、Katsumi ITOH

  DOI：10.1248/cpb.49.1102

  日期：——

  1-[(1R, 2R)-2-(2, 4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1, 2, 4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1: TAK-456) was selected as a candidate for clinical trials, but since its water-solubility was insufficient for an injectable formulation, the quaternary triazolium salts 2 were designed as water-soluble prodrugs. Among the prodrugs prepared, 4-acetoxymethyl-1-[(2R, 3R)-2-(2, 4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-1-terazolyl)phenyl]-1-imidazolidinyl]butyl]-1H-1, 2, 4-triazolium chloride (2a: TAK-457) was selected as an injectable candidate for clinical trials based on the results of evaluations on solubility, stability, hemolytic effect and in vivo antifungal activities.

  1-[(1R, 2R)-2-(2, 4-二氟苯基)-2-羟基-1-甲基-3-(1H-1, 2, 4-三唑-1-基)丙基]-3-[4-(1H-1-四唑基)苯基]-2-咪唑啉酮（1: TAK-456）被选为临床试验候选药物，但由于其水溶性不足，无法制备注射剂，因此设计了季铵三唑盐2作为水溶性前药。在制备的前药中，4-乙酰氧甲基-1-[(2R, 3R)-2-(2, 4-二氟苯基)-2-羟基-3-[2-氧代-3-[4-(1H-1-四唑基)苯基]-1-咪唑啉基]丁基]-1H-1, 2, 4-三唑氯化物（2a: TAK-457）根据溶解性、稳定性、溶血效应和体内抗真菌活性的评估结果，被选为注射剂候选药物进行临床试验。
• Optically Active Antifungal Azoles. X. Synthesis and Antifungal Activity of N-[4-(Azolyl)phenyl]- and N-[4-(Azolylmethyl)phenyl]-N'-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-azolones.
  作者：Tomoyuki KITAZAKI、Takashi ICHIKAWA、Akihiro TASAKA、Hiroshi HOSONO、Yoshihiro MATSUSHITA、Ryogo HAYASHI、Kenji OKONOGI、Katsumi ITOH

  DOI：10.1248/cpb.48.1935

  日期：——

  New optically active antifungal azoles, N-[4-(azolyl)phenyl]- and N-[4-(azolylmethyl)phenyl]-N'-[(1R, 2R)-2-(2, 4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1, 2, 4-triazol-1-yl)propyl]azolones (1, 2, 3), were prepared in a stereocontrolled manner. Compounds 1-3 showed strong antifungal activity against Candida albicans in vitro. Among them, the imidazolidinones 3 showed a broad antifungal spectrum in vitro as well as potent in vivo activity against candidiasis and aspergillosis in mice. The imidazolidinones (3i, j, k) having 1H-1, 2, 3-triazol-1-yl, 2H-2-tetrazolyl and 1H-1-tetrazolyl moieties were found to exert strong protective effect against aspergillosis.

  新型的光学活性抗真菌氮唑类化合物N-[4-(氮唑基)苯基]-和N-[4-(氮唑甲基)苯基]-N'-[(1R,2R)-2-(2,4-二氟苯基)-2-羟基-1-甲基-3-(1H-1,2,4-三唑-1-基)丙基]氮唑酮(1,2,3)通过立体控制方式制备。化合物1-3在体外表现出对白色念珠菌的强大抗真菌活性。其中，咪唑啉二酮3在体外显示出广谱抗真菌活性，并对小鼠的念珠菌病和曲霉病具有强大的体内活性。具有1H-1,2,3-三唑-1-基、2H-2-四唑基和1H-1-四唑基的咪唑啉二酮(3i,j,k)被发现对曲霉病具有强大的保护作用。
• Antimycotic drug composition
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06583164B1

  公开（公告）日：2003-06-24

  The composition of the present invention comprises a quaternized nitrogen-containing imidazole-1-yl or 1,2,4-triazole-1-yl compound wherein one of the nitrogen atoms constituting the azole ring is quaternized with a group eliminating in vivo and represented by the formula: wherein R1 represents a hydrocarbon or heterocyclic group which may be substituted, R2 represents a hydrogen atom or a lower alkyl group, and n is 0 or 1, and a saccharide, said compound being capable of being converted into an anti-fungal azole compound upon elimination of said group in vivo. The composition of the present invention is stable and usable particularly as a pharmaceutical preparation for an injection composition.

  本发明的组合物包括一种季铵化的含氮咪唑-1-基或1,2,4-三唑-1-基化合物，其中构成唑环的氮原子之一与一种在体内消除的基团季铵化，所述基团由以下公式表示： 其中R1代表可以被取代的碳氢化合物或杂环基团，R2代表氢原子或较低的烷基基团，n为0或1，并且一种糖类，所述化合物能够在体内消除所述基团后转化为抗真菌唑类化合物。本发明的组合物稳定且可用，特别适用作为注射剂组合物的制药制剂。
• The Influence of Water on the Stability of Lyophilized Formulations with Inositol and Mannitol as Excipients
  作者：Akira Terakita、Hirokazu Matsunaga、Tetsuro Handa

  DOI：10.1248/cpb.57.459

  日期：——

  The stability of a moisture-sensitive drug in lyophilized products was investigated under conditions with varying water content and temperature using two model formulations: a formulation containing inositol (IF) as the excipient and a formulation containing mannitol (MF) as the excipient. IF showed better chemical stability (a lower hydrolysis rate) than MF when both formulations contained 2% water. However, in the case of formulations with 8% water, MF showed similar or better stability than IF. From the results of hygroscopicity and phase transition experiments for both formulations, it was assumed that this stability profile was exhibited because 1) more water was taken up into the amorphous inositol in IF than into the crystalline Form-III mannitol in MF at a low water content, so that drug hydrolysis in IF was suppressed compared with MF and 2) when the water content increased, the amorphous inositol crystallized to anhydrate in IF causing expulsion of absorbed water from the excipient, meaning that IF lost its superior chemical stability due to the highly mobile water generated by the crystallization. This assumption was supported by the results of the 2H-NMR measurement, which estimated water mobility from the signal shape and the spin–lattice relaxation time (T1) of deuterium oxide.

  通过两种模型制剂研究了水分敏感药物在冻干产品中的稳定性：一种含肌醇（IF）作为辅料的制剂，另一种含甘露醇（MF）作为辅料的制剂。在两种制剂含水量均为2%的条件下，IF表现出比MF更好的化学稳定性（较低的水解速率）。然而，在含水量为8%的制剂中，MF表现出相似或更好的稳定性。根据两种制剂的吸湿性和相变实验的结果，推测这种稳定性差异的原因是：1) 在低水分含量下，IF中的无定形肌醇吸收的水分比MF中的结晶型III甘露醇更多，因此IF中药物水解受到抑制，相较MF更为明显；2) 当水分含量增加时，IF中的无定形肌醇结晶为无水物，导致辅料中吸收的水分被排出，这意味着IF因结晶产生的高流动性水分而失去了其优越的化学稳定性。2H-NMR测量的结果支持了这一假设，该测量通过信号形状和重水自旋-晶格弛豫时间（T1）估计了水分的流动性。
• Triazole Derivatives and their production
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0884311A2

  公开（公告）日：1998-12-16

  A compound of formula (I) or a salt thereof is useful as an intermediate for producing antifungal imidazolone or imidazolidinone with advantages from the industrial point of view. wherein Ar is a phenyl group which may be substituted; R1 is a hydrogen atom or lower alkyl; R2 is an aliphatic or aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R3 is a group of the formula -CH2Y (wherein Y is a hydroxyl group or a halogen atom) or a formyl group which may be protected.

  式(I)化合物或其盐可作为生产抗真菌咪唑啉酮或咪唑啉酮的中间体，具有工业优势。 其中 Ar 为可被取代的苯基；R1 为氢原子或低级烷基；R2 为可被取代的脂肪族或芳香族烃基或可被取代的芳香族杂环基；R3 为式 -CH2Y 的基团（其中 Y 为羟基或卤原子）或可被保护的甲酰基。